Mark G Kris

6PUBLICATIONS
101CO-AUTHORS
Molecular targetsPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Oct 05, 2026
Type II ROS1 Inhibition Overcomes Type I Inhibitor Resistance in ROS1 Fusion-Positive Lung Cancers: A Phase II Trial of Cabozantinib.

|Aug 27, 2026
A Phase 2 Basket Trial of Ado-Trastuzumab Emtansine for Patients with HER2 Amplified Cancers: A Non-Randomized Clinical Trial.

|Jun 24, 2026
The Genomic Landscape of MYC-, MYCL-, and MYCN-Amplified Solid Tumors.

|Jun 26, 2024
Tumor-Agnostic Genomic and Clinical Analysis of BRAF Fusions Identifies Actionable Targets.

Monica F Chen, Soo-Ryum Yang, Jessica J Tao

|Jul 11, 2023
Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer.

Rohit Thummalapalli, Biagio Ricciuti, Chaitanya Bandlamudi

|Feb 02, 2023
Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in EGFR-Mutant Lung Adenocarcinomas.

Arielle Elkrief, Alex Makhnin, Khadeja A Moses

Pageof 1

Frequent Collaborators

4 joint publications

Alexander Drilon

4 joint publications

Gregory J Riely

3 joint publications

Clare Wilhelm

3 joint publications

Mark T A Donoghue